Trials / Completed
CompletedNCT00532207
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Efficacy and Safety of Teriparatide 20 Micrograms in the Treatment of Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | teriparatide | subcutaneous 20 micrograms |
Timeline
- Start date
- 2003-11-01
- Completion
- 2004-12-01
- First posted
- 2007-09-20
- Last updated
- 2007-09-20
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT00532207. Inclusion in this directory is not an endorsement.